These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 32303763)

  • 1. Acute cognitive effects of the hypocretin receptor antagonist almorexant relative to zolpidem and placebo: a randomized clinical trial.
    Neylan TC; Richards A; Metzler TJ; Ruoff LM; Varbel J; O'Donovan A; Sivasubramanian M; Motraghi T; Hlavin J; Batki SL; Inslicht SS; Samuelson K; Morairty SR; Kilduff TS
    Sleep; 2020 Oct; 43(10):. PubMed ID: 32303763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Dual Hypocretin Receptor Antagonist Almorexant is Permissive for Activation of Wake-Promoting Systems.
    Parks GS; Warrier DR; Dittrich L; Schwartz MD; Palmerston JB; Neylan TC; Morairty SR; Kilduff TS
    Neuropsychopharmacology; 2016 Mar; 41(4):1144-55. PubMed ID: 26289145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute Cognitive Effects of the Dual Orexin Receptor Antagonist Lemborexant Compared With Suvorexant and Zolpidem in Recreational Sedative Users.
    Landry I; Hall N; Alur J; Filippov G; Reyderman L; Setnik B; Henningfield J; Moline M
    J Clin Psychopharmacol; 2022 Jul-Aug 01; 42(4):374-382. PubMed ID: 35748777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypocretin/orexin antagonism enhances sleep-related adenosine and GABA neurotransmission in rat basal forebrain.
    Vazquez-DeRose J; Schwartz MD; Nguyen AT; Warrier DR; Gulati S; Mathew TK; Neylan TC; Kilduff TS
    Brain Struct Funct; 2016 Mar; 221(2):923-40. PubMed ID: 25431268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The hypocretin/orexin antagonist almorexant promotes sleep without impairment of performance in rats.
    Morairty SR; Wilk AJ; Lincoln WU; Neylan TC; Kilduff TS
    Front Neurosci; 2014; 8():3. PubMed ID: 24550767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of lemborexant versus placebo and zolpidem: effects on auditory awakening threshold, postural stability, and cognitive performance in healthy older participants in the middle of the night and upon morning awakening.
    Murphy P; Kumar D; Zammit G; Rosenberg R; Moline M
    J Clin Sleep Med; 2020 May; 16(5):765-773. PubMed ID: 32022664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the abuse liability of a dual orexin receptor antagonist: a crossover study of almorexant and zolpidem in recreational drug users.
    Cruz HG; Hoever P; Chakraborty B; Schoedel K; Sellers EM; Dingemanse J
    CNS Drugs; 2014 Apr; 28(4):361-72. PubMed ID: 24627301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Locus Coeruleus and Tuberomammillary Nuclei Ablations Attenuate Hypocretin/Orexin Antagonist-Mediated REM Sleep.
    Schwartz MD; Nguyen AT; Warrier DR; Palmerston JB; Thomas AM; Morairty SR; Neylan TC; Kilduff TS
    eNeuro; 2016; 3(2):. PubMed ID: 27022631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of almorexant in adult chronic insomnia: a randomized placebo-controlled trial with an active reference.
    Black J; Pillar G; Hedner J; Polo O; Berkani O; Mangialaio S; Hmissi A; Zammit G; Hajak G
    Sleep Med; 2017 Aug; 36():86-94. PubMed ID: 28735928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy.
    Black SW; Morairty SR; Fisher SP; Chen TM; Warrier DR; Kilduff TS
    Sleep; 2013 Mar; 36(3):325-36. PubMed ID: 23449602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of zolpidem and zaleplon on cognitive performance after emergent morning awakenings at Tmax: a randomized placebo-controlled trial.
    Dinges DF; Basner M; Ecker AJ; Baskin P; Johnston SL
    Sleep; 2019 Mar; 42(3):. PubMed ID: 30576525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive performance following premature awakening from zolpidem or melatonin induced daytime sleep.
    Storm WF; Eddy DR; Welch CB; Hickey PA; Fischer J; Cardenas R
    Aviat Space Environ Med; 2007 Jan; 78(1):10-20. PubMed ID: 17225476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users.
    Landry I; Hall N; Aluri J; Filippov G; Reyderman L; Setnik B; Henningfield J; Moline M
    J Clin Psychopharmacol; 2022 Jul-Aug 01; 42(4):365-373. PubMed ID: 35749758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of insomnia treatment with lemborexant in older adults: analyses from three clinical trials.
    Gotfried MH; Auerbach SH; Dang-Vu TT; Mishima K; Kumar D; Moline M; Malhotra M
    Drugs Aging; 2024 Sep; 41(9):741-752. PubMed ID: 39120786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance.
    Verster JC; Volkerts ER; Schreuder AH; Eijken EJ; van Heuckelum JH; Veldhuijzen DS; Verbaten MN; Paty I; Darwish M; Danjou P; Patat A
    J Clin Psychopharmacol; 2002 Dec; 22(6):576-83. PubMed ID: 12454557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of the dual orexin receptor antagonist almorexant and the GABA(A)-α1 receptor modulator zolpidem, alone or combined with ethanol, on motor performance in the rat.
    Steiner MA; Lecourt H; Strasser DS; Brisbare-Roch C; Jenck F
    Neuropsychopharmacology; 2011 Mar; 36(4):848-56. PubMed ID: 21150905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of alcohol, zolpidem, and some other sedatives and hypnotics on human performance and memory.
    Mattila MJ; Vanakoski J; Kalska H; Seppälä T
    Pharmacol Biochem Behav; 1998 Apr; 59(4):917-23. PubMed ID: 9586849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute effects of zolpidem extended-release on cognitive performance and sleep in healthy males after repeated nightly use.
    Kleykamp BA; Griffiths RR; McCann UD; Smith MT; Mintzer MZ
    Exp Clin Psychopharmacol; 2012 Feb; 20(1):28-39. PubMed ID: 21928913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance.
    Troy SM; Lucki I; Unruh MA; Cevallos WH; Leister CA; Martin PT; Furlan PM; Mangano R
    J Clin Psychopharmacol; 2000 Jun; 20(3):328-37. PubMed ID: 10831020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation.
    Beuckmann CT; Ueno T; Nakagawa M; Suzuki M; Akasofu S
    Sleep; 2019 Jun; 42(6):. PubMed ID: 30923834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.